[Ac 225]RTX-2358

Phase 1

RRatio Therapeutics, Inc.

[Ac 225]RTX-2358 is one of 18 therapeutic programs targeting Advanced Soft-tissue Sarcoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Soft-Tissue SarcomaRecruiting

Advanced Soft-Tissue SarcomaPhase 1

Recruiting

Competition

Competitive Landscape

18 competitors in Advanced Soft-Tissue Sarcoma

#DrugCompanyPhaseTrials

Tykerb

GSK

Phase 3

1 2

Zykadia

Novartis

Phase 3

1 3

Tabrecta

Novartis

Phase 3

1 4

Ibrance

Pfizer

Phase 3

1 5

Mekinist

Novartis

Phase 3

1 6

Tasigna

AAzurity Pharmaceuticals

Phase 3

1 7

Adriamycin

Pfizer

Phase 2

2 8

Gemzar

Johnson & Johnson

Phase 2

1 9

Daurismo

Pfizer

Phase 3

1 10

Xpovio

KKaryopharm Therapeutics Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 1Recruiting

Advanced Soft-Tissue Sarcoma

NCT07156565

Clinical

Trials by Indication[1]

Advanced Soft-tissue Sarcoma1 trial

A Seamless Phase 1/2 Open-label Study to Evaluate the Safety, Determine the Maximum Tolerated Dose of Administered Activity, and Evaluate the Efficacy of the Therapeutic Radiopharmaceutical [Ac 225]-RTX-2358 in the Treatment of Relapsed or Refractory Sarcoma

Recruiting·RRatio Therapeutics, Inc.·Phase 1·NCT07156565·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [Ac 225]RTX-2358. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [Ac 225]RTX-2358. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ratio Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: RRatio Therapeutics, Inc.

[Ac 225]RTX-2358

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Advanced Soft-tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News